{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:21:56Z","timestamp":1790846516850,"version":"4.1.0"},"reference-count":125,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Marine Drugs"],"abstract":"<jats:p>Dolastatin 10 (Dol-10), a leading marine pentapeptide isolated from the Indian Ocean mollusk Dolabella auricularia, contains three unique amino acid residues. Dol-10 can effectively induce apoptosis of lung cancer cells and other tumor cells at nanomolar concentration, and it has been developed into commercial drugs for treating some specific lymphomas, so it has received wide attention in recent years. In vitro experiments showed that Dol-10 and its derivatives were highly lethal to common tumor cells, such as L1210 leukemia cells (IC50 = 0.03 nM), small cell lung cancer NCI-H69 cells (IC50 = 0.059 nM), and human prostate cancer DU-145 cells (IC50 = 0.5 nM), etc. With the rise of antibody-drug conjugates (ADCs), milestone progress was made in clinical research based on Dol-10. A variety of ADCs constructed by combining MMAE or MMAF (Dol-10 derivatives) with a specific antibody not only ensured the antitumor activity of the drugs themself but also improved their tumor targeting and reduced the systemic toxicity. They are currently undergoing clinical trials or have been approved for marketing, such as Adcetris\u00ae, which had been approved for the treatment of anaplastic large T-cell systemic malignant lymphoma and Hodgkin lymphoma. Dol-10, as one of the most medically valuable natural compounds discovered up to now, has brought unprecedented hope for tumor treatment. It is particularly noteworthy that, by modifying the chemical structure of Dol-10 and combining with the application of ADCs technology, Dol-10 as a new drug candidate still has great potential for development. In this review, the biological activity and chemical work of Dol-10 in the advance of antitumor drugs in the last 35 years will be summarized, which will provide the support for pharmaceutical researchers interested in leading exploration of antitumor marine peptides.<\/jats:p>","DOI":"10.3390\/md19070363","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T11:01:38Z","timestamp":1624532498000},"page":"363","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry"],"prefix":"10.3390","volume":"19","author":[{"given":"Gang","family":"Gao","sequence":"first","affiliation":[{"name":"School of Medicine, Ningbo University, 818 Fenghua Road, Ningbo 315211, China"},{"name":"Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Hua","sequence":"additional","affiliation":[{"name":"Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-4619","authenticated-orcid":false,"given":"Dahong","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlan","family":"Tang","sequence":"additional","affiliation":[{"name":"School of Medicine, Ningbo University, 818 Fenghua Road, Ningbo 315211, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1039\/C7NP00052A","article-title":"Marine natural products","volume":"35","author":"Blunt","year":"2018","journal-title":"Nat. Prod. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1039\/C9NP00069K","article-title":"Marine natural products","volume":"37","author":"Carroll","year":"2020","journal-title":"Nat. Prod. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1039\/b006897g","article-title":"Marine natural products","volume":"19","author":"Faulkner","year":"2001","journal-title":"Nat. Prod. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dyshlovoy, S.A., and Honecker, F. (2019). Marine Compounds and Cancer: The First Two Decades of XXI Century. Mar. Drugs, 18.","DOI":"10.3390\/md18010020"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.32607\/20758251-2009-1-2-15-25","article-title":"Marine Natural Products: A Way to New Drugs","volume":"1","author":"Stonik","year":"2009","journal-title":"Acta Nat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1126\/science.1116364","article-title":"The Renaissance of Natural Products as Drug Candidates","volume":"310","author":"Paterson","year":"2005","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrd2487","article-title":"Drug development from marine natural products","volume":"8","author":"Molinski","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Jing, Q., Hu, X., Ma, Y., Mu, J., Liu, W., Xu, F., Li, Z., Bai, J., Hua, H., and Li, D. (2019). Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification. Mar. Drugs, 17.","DOI":"10.3390\/md17070384"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chen, J., Wang, B., Lu, Y., Guo, Y., Sun, J., Wei, B., Zhang, H., and Wang, H. (2019). Quorum Sensing Inhibitors from Marine Microorganisms and Their Synthetic Derivatives. Mar. Drugs, 17.","DOI":"10.3390\/md17020080"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Choudhary, A., Naughton, L.M., Mont\u00e1nchez, I., Dobson, A.D.W., and Rai, D.K. (2017). Current Status and Future Prospects of Marine Natural Products (MNPs) as Antimicrobials. Mar. Drugs, 15.","DOI":"10.3390\/md15090272"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/17460441.2019.1604675","article-title":"Have marine natural product drug discovery efforts been productive and how can we improve their efficiency?","volume":"14","author":"Pereira","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Huang, C., Zhang, Z., and Cui, W. (2019). Marine-Derived Natural Compounds for the Treatment of Parkinson\u2019s Disease. Mar. Drugs, 17.","DOI":"10.3390\/md17040221"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2018.10.003","article-title":"Marine sponges of the genus Stelletta as promising drug sources: Chemical and biological aspects","volume":"9","author":"Wu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_14","unstructured":"Livingston, D.M., and Kung, A.L. (2009). Composition and Method for Imaging Cells. (US20090185977A1)."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00044-016-1730-8","article-title":"TNF-\u03b1 and IL-6 inhibitory effects of cyclic dipeptides isolated from marine bacteria Streptomyces sp.","volume":"26","author":"Nalli","year":"2017","journal-title":"Med. Chem. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/1574892813666180430110033","article-title":"Recent Progress of Marine Polypeptides as Anticancer Agents","volume":"13","author":"Zheng","year":"2018","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sable, R., Parajuli, P., and Jois, S. (2017). Peptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications. Mar. Drugs, 15.","DOI":"10.3390\/md15040124"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1389201016666150817095537","article-title":"Screening for Marine Natural Products with Potential as Chemotherapeutics for Acute Myeloid Leukemia","volume":"17","author":"Hansen","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3390\/md9101840","article-title":"Antitumor Peptides from Marine Organisms","volume":"9","author":"Zheng","year":"2011","journal-title":"Mar. Drugs"},{"key":"ref_20","first-page":"01","article-title":"Development of Co-production of Polysaccharides and Polypeptides from Marine Organisms\u2014A Review","volume":"9","author":"Daqiao","year":"2019","journal-title":"Chin. Fish. Qual. Stand."},{"key":"ref_21","first-page":"1208","article-title":"Research advances on marine antitumor peptides dolastatin 10","volume":"24","author":"Cao","year":"2011","journal-title":"J. Med. Postgrad."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2174\/1389203717666160724200849","article-title":"Marine Peptides as Anticancer Agents: A Remedy to Mankind by Nature","volume":"18","author":"Negi","year":"2017","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_23","first-page":"54","article-title":"Advances in the application of marine bioactive peptide drugs","volume":"38","author":"Cui","year":"2019","journal-title":"Chin. J. Mar. Drugs"},{"key":"ref_24","first-page":"149","article-title":"The classification and advances of bioactive peptides","volume":"14","author":"Ma","year":"2019","journal-title":"Chin. J. Inj. Rep. Wound Heal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.tet.2012.01.097","article-title":"Anti-inflammatory cyclopeptides from the marine sponge Theonella swinhoei","volume":"68","author":"Festa","year":"2012","journal-title":"Tetrahedron"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(03)00655-8","article-title":"Marine natural products and their potential applications as anti-infective agents","volume":"3","author":"Donia","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/187152008785133074","article-title":"Clinical status of anti-cancer agents derived from marine sources","volume":"8","author":"Joshi","year":"2008","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.foodres.2015.05.013","article-title":"Biologically active peptides: Processes for their generation, purification and identification and applications as natural additives in the food and pharmaceutical industries","volume":"74","author":"Sato","year":"2015","journal-title":"Food Res. Int."},{"key":"ref_29","first-page":"1","article-title":"[Fortschritte der Chemie organischer Naturstoffe\/Progress in the Chemistry of Organic Natural Products] Fortschritte der Chemie organischer Naturstoffe Progress in the Chemistry of Organic Natural Products","volume":"70","author":"Cortes","year":"1997","journal-title":"Dolastatins"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1021\/ja00256a070","article-title":"The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10","volume":"109","author":"Pettit","year":"1987","journal-title":"J. Am. Chem. Soc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9151","DOI":"10.1016\/0040-4020(93)80003-C","article-title":"Antineoplastic Agents. Part 247. The Dolastatins. Part 18. Isolation of Dolastatins 10\u201315 from the Marine Mollusc Dolabella auricularia","volume":"49","author":"Pettit","year":"1993","journal-title":"Tetrahedron"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1021\/np800568j","article-title":"Tubulin-Interactive Natural Products as Anticancer Agents","volume":"72","author":"Kingston","year":"2009","journal-title":"J. Nat. Prod."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0006-2952(93)90051-W","article-title":"Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin","volume":"45","author":"Bai","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/0006-2952(90)90367-T","article-title":"Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10","volume":"40","author":"Bai","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0006-2952(90)90613-P","article-title":"Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain","volume":"39","author":"Bai","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00001813-199605000-00016","article-title":"Effect of dolastatin 10 on human non-Hodgkin\u2019s lymphoma cell lines","volume":"7","author":"Maki","year":"1996","journal-title":"Anticancer Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s002800050931","article-title":"Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification","volume":"43","author":"Kalemkerian","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1097-0045(19980215)34:3<175::AID-PROS4>3.0.CO;2-H","article-title":"Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc","volume":"34","author":"Turner","year":"1998","journal-title":"Prostate"},{"key":"ref_39","unstructured":"Pettit, G.R., Srirangam, J.K., Williams, M.D., Durkin, K.P.M., Barlozzari, T., Kling, A., Janssen, B., and Haupt, A. (2001). Dolastatin Peptides. (US6323315B1)."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/np50016a016","article-title":"Marine Animal Biosynthetic Constituents For Cancer Chemotherapy","volume":"44","author":"Pettit","year":"1981","journal-title":"J. Nat. Prod."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1039\/b514294f","article-title":"Natural products to drugs: Natural product-derived compounds in clinical trials","volume":"25","author":"Butler","year":"2008","journal-title":"Nat. Prod. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1021\/ja00196a061","article-title":"Antineoplastic Agents.189. The Absolute-Configuration and Synthesis of Natural (-)-Dolastatin-10","volume":"111","author":"Pettit","year":"1989","journal-title":"J. Am. Chem. Soc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/1535-7163.333.4.2","article-title":"Marine natural products as anticancer drugs","volume":"4","author":"Simmons","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","first-page":"525","article-title":"Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors","volume":"5","author":"Pitot","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1349-7006.2008.01023.x","article-title":"Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks","volume":"100","author":"Yamamoto","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-007-0665-7","article-title":"Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer","volume":"62","author":"Horti","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0090-8258(03)00007-6","article-title":"A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study","volume":"89","author":"Hoffman","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_49","first-page":"180","article-title":"Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity","volume":"57","author":"Kepler","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jnci\/85.6.483","article-title":"Growth Inhibition of Human Lymphoma Cell Lines by the Marine Products, Dolastatins 10 and 15","volume":"85","author":"Beckwith","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00001813-199802000-00006","article-title":"Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma","volume":"9","author":"Mohammad","year":"1998","journal-title":"Anti-Cancer Drugs"},{"key":"ref_52","first-page":"4205","article-title":"Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma","volume":"6","author":"Vaishampayan","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1155\/2004\/924913","article-title":"Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas","volume":"8","author":"Von","year":"2004","journal-title":"Sarcoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10637-005-6735-y","article-title":"Phase II trial of dolastatin-10 in patients with advanced breast cancer","volume":"23","author":"Perez","year":"2005","journal-title":"Investig. New Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-005-2909-x","article-title":"Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers","volume":"23","author":"Kindler","year":"2005","journal-title":"Investig. New Drugs"},{"key":"ref_56","first-page":"309","article-title":"Tubulin and microtubules as targets for anticancer drugs","volume":"5","author":"Hadfield","year":"2003","journal-title":"Prog. Cell Cycle Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance","volume":"8","author":"Perez","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1158\/1078-0432.CCR-08-0169","article-title":"Microtubule Active Agents: Beyond the Taxane Frontier","volume":"14","author":"Morris","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/iub.25","article-title":"Microtubules: A dynamic target in cancer therapy","volume":"60","author":"Pasquier","year":"2008","journal-title":"Iubmb Life"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1054\/drup.2002.0230","article-title":"Anticancer therapy with novel tubulin-interacting drugs","volume":"4","author":"Kavallaris","year":"2001","journal-title":"Drug Resist. Updat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14707","DOI":"10.1074\/jbc.271.25.14707","article-title":"Localization of the Vinblastine-binding Site on \u03b2-Tubulin","volume":"271","author":"Rai","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0009-2797(94)90018-3","article-title":"Interaction of marine toxin dolastatin 10 with porcine brain tubulin: Competitive inhibition of rhizoxin and phomopsin A binding","volume":"93","author":"Li","year":"1994","journal-title":"Chem. Interact."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0006-2952(92)90576-5","article-title":"Interaction of dolastatin 10 with bovine brain tubulin","volume":"43","author":"Luduena","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1016\/S0021-9258(17)44880-0","article-title":"Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites","volume":"265","author":"Bai","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"12063","DOI":"10.1016\/S0021-9258(20)71320-7","article-title":"Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin","volume":"259","author":"Roach","year":"1984","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0003-9861(81)90214-9","article-title":"Contrasting effects of maytansine and vinblastine on the alkylation of tubulin sulfhydryls","volume":"210","author":"Roach","year":"1981","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0167-4838(87)90243-3","article-title":"Location of two cysteines in brain beta 1-tubulin that can be cross-linked after removal of exchangeable GTP","volume":"912","author":"Little","year":"1987","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/0006-2952(90)90527-R","article-title":"Effect of phomopsin a on the alkylation of tubulin","volume":"39","author":"Roach","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"13955","DOI":"10.1021\/bi0487387","article-title":"Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin","volume":"43","author":"Mitra","year":"2004","journal-title":"Biochemistry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"30731","DOI":"10.1074\/jbc.M402110200","article-title":"Direct photoaffinity labeling by dolastatin 10 of the amino-terminal peptide of beta-tubulin containing cysteine 12","volume":"279","author":"Bai","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00001813-199506000-00005","article-title":"The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma","volume":"6","author":"Maki","year":"1995","journal-title":"Anti-Cancer Drugs"},{"key":"ref_72","first-page":"1609","article-title":"Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells","volume":"58","author":"Haldar","year":"1998","journal-title":"Cancer Res."},{"key":"ref_73","first-page":"373","article-title":"Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line","volume":"5","author":"Pathak","year":"1998","journal-title":"Oncol. Rep."},{"key":"ref_74","first-page":"323","article-title":"Telomeric association of chromosomes is an early manifestation of programmed cell death","volume":"4","author":"Pathak","year":"1994","journal-title":"Int. J. Oncol."},{"key":"ref_75","first-page":"843","article-title":"Chromosome alterations in cancer development and apoptosis","volume":"8","author":"Pathak","year":"1994","journal-title":"In Vivo"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002800050475","article-title":"Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay","volume":"38","author":"Aherne","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002800050743","article-title":"Quantitation of dolastatin-10 using HPLC\/electrospray ionization mass spectrometry: Application in a phase I clinical trial","volume":"41","author":"Garteiz","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_78","first-page":"1293","article-title":"Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors","volume":"6","author":"Madden","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s002800050995","article-title":"Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance","volume":"44","author":"Mirsalis","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00280-001-0402-6","article-title":"Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia","volume":"49","author":"Thamm","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.cco.0000228740.70379.3f","article-title":"ET-743: A novel agent with activity in soft-tissue sarcomas","volume":"18","author":"Fayette","year":"2006","journal-title":"Curr. Opin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0006-2952(94)90292-5","article-title":"Role of P-glycoprotein in dolastatin 10 resistance","volume":"48","author":"Toppmeyer","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1021\/acsomega.8b00093","article-title":"Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications","volume":"3","author":"Akaiwa","year":"2018","journal-title":"ACS Omega"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acs.jnatprod.7b00359","article-title":"Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains","volume":"80","author":"Barnscher","year":"2017","journal-title":"J. Nat. Prod."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"10527","DOI":"10.1021\/jm501649k","article-title":"Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications","volume":"57","author":"Maderna","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_86","first-page":"243","article-title":"Antineoplastic agents 365. Dolastatin 10 SAR probes","volume":"13","author":"Pettit","year":"1998","journal-title":"Anticancer Drug Des."},{"key":"ref_87","first-page":"806","article-title":"Auristatin PYE, a novel synthetic derivative of dolastatin 10: Activity and mechanistic studies in a colon adenocarcinoma model","volume":"65","author":"Shnyder","year":"2005","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.bjc.6603769","article-title":"The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo","volume":"96","author":"Akashi","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_89","first-page":"1973","article-title":"Antitumor activity of TZT-1027 (Soblidotin)","volume":"26","author":"Watanabe","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1349-7006.2003.tb01526.x","article-title":"Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo","volume":"94","author":"Natsume","year":"2003","journal-title":"Cancer Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.bmc.2018.02.011","article-title":"Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations","volume":"26","author":"Yokosaka","year":"2018","journal-title":"Bioorganic Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/np1007334","article-title":"Antineoplastic Agents. 592. Highly Effective Cancer Cell Growth Inhibitory Structural Modifications of Dolastatin 10","volume":"74","author":"Pettit","year":"2011","journal-title":"J. Nat. Prod."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1021\/acs.jnatprod.0c00031","article-title":"Antineoplastic Agents. 607. Emetine Auristatins","volume":"83","author":"Pettit","year":"2020","journal-title":"J. Nat. Prod."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1021\/jm00174a006","article-title":"Chiral modifications of dolastatin 10: The potent cytostatic peptide (19aR)-isodolastatin 10","volume":"33","author":"Pettit","year":"1990","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1039\/C9QO01292C","article-title":"A diastereoselective approach to amino alcohols and application for divergent synthesis of dolastatin 10","volume":"7","author":"Nie","year":"2020","journal-title":"Org. Chem. Front."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1021\/jm970800t","article-title":"Synthesis and Biological Activity of Chimeric Structures Derived from the Cytotoxic Natural Compounds Dolastatin 10 and Dolastatin 15","volume":"41","author":"Poncet","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.tet.2017.03.006","article-title":"Synthesis and biological activity evaluation of dolastatin 10 analogues with N-terminal modifications","volume":"73","author":"Wang","year":"2017","journal-title":"Tetrahedron"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1039\/C7OB01395G","article-title":"A practical approach to asymmetric synthesis of dolastatin 10","volume":"15","author":"Zhou","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1039\/C9OB01639B","article-title":"Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody\u2013drug conjugation","volume":"17","author":"Yang","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"ref_100","first-page":"195","article-title":"Application of fluorescence imaging in the research of tumor","volume":"22","author":"Zhang","year":"2009","journal-title":"J. Med. Postgrad."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1158\/1078-0432.CCR-10-0017","article-title":"EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma","volume":"16","author":"Lee","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/jnci\/djp231","article-title":"EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma","volume":"101","author":"Lee","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2020.04.031","article-title":"Phase II results from a phase I\/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network","volume":"135","author":"Amoroso","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10637-012-9801-2","article-title":"Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors","volume":"31","author":"Annunziata","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_105","first-page":"311","article-title":"Novel antibodies in the treatment of non-Hodgkin\u2019s lymphoma","volume":"67","author":"Bhat","year":"2009","journal-title":"Neth. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","article-title":"Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: Target and linker-drug selection","volume":"69","author":"Polson","year":"2009","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1021\/acs.jnatprod.6b01006","article-title":"Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors","volume":"80","author":"Pettit","year":"2017","journal-title":"J. Nat. Prod."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1021\/acs.jnatprod.7b00237","article-title":"Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates","volume":"80","author":"Pettit","year":"2017","journal-title":"J. Nat. Prod."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1021\/acs.jnatprod.7b00352","article-title":"Antineoplastic Agents. 605. Isoquinstatins","volume":"81","author":"Pettit","year":"2018","journal-title":"J. Nat. Prod."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1248\/cpb.43.1706","article-title":"Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs","volume":"43","author":"Miyazaki","year":"1995","journal-title":"Chem. Pharm. Bull."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0040-4020(01)80547-0","article-title":"Stereoselective synthesis of dolastatin 10 and its congeners","volume":"49","author":"Shioiri","year":"1993","journal-title":"Tetrahedron"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1016\/S0960-894X(98)00511-3","article-title":"Synthesis and antiproliferative activity of a cyclic analog of dolastatin 10","volume":"8","author":"Poncet","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/0040-4020(95)00008-V","article-title":"Conformational study of dolastatin 10","volume":"51","author":"Alattia","year":"1995","journal-title":"Tetrahedron"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.1016\/S0040-4020(97)00504-8","article-title":"Isolation and stereostructure of dolastatin I, a cytotoxic cyclic hexapeptide from the Japanese sea hare Dolabella auricularia","volume":"53","author":"Sone","year":"1997","journal-title":"Tetrahedron"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Tomioka, K., Satoh, M., Taniyama, D., Kanai, M., and Iida, A. (1998). ChemInform Abstract: Enantioselective Addition of Thiazolyllithium to Aldimines with the Aid of Chiral Ligand. Asymmetric Synthesis of (S)-Doe, a Component of Marine Natural Product, Dolastatin 10. Cheminform, 29.","DOI":"10.1002\/chin.199818142"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0040-4039(00)92123-3","article-title":"Efficient stereoselective synthesis of dolastatin 10, an antineoplastic peptide from a sea hare","volume":"32","author":"Hamada","year":"1991","journal-title":"Tetrahedron Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1055\/s-0031-1289594","article-title":"A Straightforward Approach to Protected (S)-Dolaphenine (Doe), the Unusual Amino Acid Component of Dolastatin 10","volume":"2011","author":"Kazmaier","year":"2011","journal-title":"Synthesis"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1002\/chin.200740180","article-title":"Total Synthesis of Dolastatin 10 Through Ruthenium-Catalyzed Asymmetric Hydrogenations","volume":"38","author":"Mordant","year":"2007","journal-title":"ChemInform"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0040-4039(00)79932-1","article-title":"An expeditious synthesis of dolastatin 10","volume":"32","author":"Kiyoshi","year":"1991","journal-title":"Tetrahedron Lett."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Pettit, G.R., Singh, S.B., Hogan, F., Lloyd-Williams, P., Herald, D.L., Burkett, D.D., and Clewlow, P.J. (1989). ChemInform Abstract: Antineoplastic Agents. Part 189. The Absolute Configuration and Synthesis of Natural (-)-Dolastatin 10. ChemInform, 20.","DOI":"10.1002\/chin.198943277"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/bip.360360414","article-title":"Conformational analysis of dolastatin 10: An nmr and theoretical approach","volume":"36","author":"Benedetti","year":"1995","journal-title":"Biopolymers"},{"key":"ref_122","first-page":"205","article-title":"The Conformational Properties of (-)-Dolastatin 10, a Powerful Antineoplastic Agent","volume":"11","author":"Fantucci","year":"1994","journal-title":"Mol. Electron."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF00124000","article-title":"Conformational behaviour of the antineoplastic peptide dolastatin-10 and of two mutated derivatives","volume":"9","author":"Fantucci","year":"1995","journal-title":"J. Comput. Mol. Des."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1128\/AAC.42.11.2961","article-title":"Specific Activities of Dolastatin 10 and Peptide Derivatives against Cryptococcus neoformans","volume":"42","author":"Pettit","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/jac\/dkg151","article-title":"Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum","volume":"51","author":"Fennell","year":"2003","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Marine Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-3397\/19\/7\/363\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:23:06Z","timestamp":1760163786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-3397\/19\/7\/363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":125,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["md19070363"],"URL":"https:\/\/doi.org\/10.3390\/md19070363","relation":{},"ISSN":["1660-3397"],"issn-type":[{"value":"1660-3397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]}}}